Journey Strategic Wealth LLC Invests $445,000 in Hims & Hers Health, Inc. $HIMS

Journey Strategic Wealth LLC bought a new position in Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to its most recent filing with the SEC. The firm bought 8,928 shares of the company’s stock, valued at approximately $445,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Nuveen LLC bought a new position in shares of Hims & Hers Health in the first quarter valued at $58,403,000. State of Michigan Retirement System raised its holdings in shares of Hims & Hers Health by 84.9% in the 2nd quarter. State of Michigan Retirement System now owns 1,379,100 shares of the company’s stock worth $68,748,000 after acquiring an additional 633,300 shares during the last quarter. Jump Financial LLC raised its holdings in shares of Hims & Hers Health by 633.2% in the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock worth $21,437,000 after acquiring an additional 626,496 shares during the last quarter. Northern Trust Corp lifted its position in Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares in the last quarter. Finally, Steadview Capital Management LLC acquired a new position in Hims & Hers Health during the 2nd quarter valued at about $19,442,000. Institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the sale, the chief financial officer owned 128,984 shares of the company’s stock, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $53.48, for a total value of $6,852,231.96. Following the transaction, the chief executive officer directly owned 160,425 shares of the company’s stock, valued at approximately $8,579,529. This trade represents a 44.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 630,583 shares of company stock worth $33,544,943 over the last three months. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Stock Up 3.2%

HIMS stock opened at $34.71 on Friday. The stock has a market cap of $7.90 billion, a P/E ratio of 64.28, a P/E/G ratio of 6.91 and a beta of 2.20. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The stock’s fifty day simple moving average is $49.10 and its two-hundred day simple moving average is $51.15. Hims & Hers Health, Inc. has a 1-year low of $23.03 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The business had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its Board of Directors has initiated a stock buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several brokerages have recently commented on HIMS. BTIG Research reissued a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Canaccord Genuity Group reissued a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Wall Street Zen cut Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, November 17th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $45.27.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.